Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Effects of EMG-driven Robot-assisted Therapy for the Distal Upper Limb Motor Function in the Chronic Stroke Patients With Botox Injections

NCT04502264 · Cheng-Hsin General Hospital · Updated 19 March 2024

What is being tested
Hand of Hope; Botulinum toxin type A injection
For
Chronic Stroke; Spasticity as Sequela of Stroke; Robotic Rehabilitation
Kind of study
Tests a treatment or device on volunteers. Phase 2.
Who can join
Ages 20 years to 85 years. About 24 people. The full rules are on the registry page.
Where
Taiwan
When
Starts or started 9 Jan 2020, ends 9 Feb 2024. Registered 6 Aug 2020.
Results
None posted yet.

In the researchers' words

Over fifty percent of stroke patients experience chronic arm hand performance problems, compromising independence in daily life activities and quality of life. Traditionally, the effectiveness of rehabilitation in improving functioning for stroke patients more than 6 months has not been proven. However, spontaneous neurological recovery reaches the plateau at 3\~6 months later. Hand of Hope is a virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot. Otherwise, it needs patients to have active participation during the intervention which is critical for motor recovery after stroke. Robotic rehabilitation devices have the potential to deliver high-intensity, reproducible therapy. Robot-assisted task-oriented training had been proposed by several researchers, but the evidence of clinical effectiveness in highly functional chronic stroke patients is still lack. Spasticity is a common disorder which occurs following stroke. The prevalence of post-stroke spasticity can be as high as 46% in the chronic phase (over 3 months). Spasticity impacted activities of daily living, quality of life, pain, and functional impairments. Long-term spasticity may lead to tendon contracture and limb deformities. Botulinum toxin injection, which mostly used in chronic phase (over 6 months), had been proved to be a safe agent representing the gold standard treatment…
ClinicalTrials.gov, NCT04502264

Sites

  • Cheng-Hsin general hospitalTaipei, Taiwan